Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $175.00 short put and a strike $165.00 long put offers a potential 16.82% return on risk over the next 36 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $175.00 by expiration. The full premium credit of $1.44 would be kept by the premium seller. The risk of $8.56 would be incurred if the stock dropped below the $165.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 74.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Cramer: The Airlines and Health-Care Names Are Really Soaring
Wed, 15 Mar 2017 23:01:00 GMT
Jim Cramer: Amgen’s Pipeline Positions It Well to Withstand a Rate Hike
Wed, 15 Mar 2017 15:48:00 GMT
Cramer’s Stop Trading: Amgen’s pipeline
Wed, 15 Mar 2017 13:55:00 GMT
Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In ‘JAMA Cardiology’
Tue, 14 Mar 2017 20:15:00 GMT
PR Newswire – THOUSAND OAKS, Calif., March 14, 2017 /PRNewswire/ — Amgen (AMGN) today announced that four-year follow-up results from the Repatha® (evolocumab) OSLER-1 study, the longest PCSK9 inhibitor clinical trial to date, were published in JAMA Cardiology. “For patients with cardiovascular disease, persistent LDL-C reduction is an important component of managing this chronic disease,” said Michael J. Koren, M.D., Jacksonville Center for Clinical Research.
Also on Market Tamer…
Follow Us on Facebook